An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future

Ropeginterferon alfa-2b is a novel, long-acting mono-pegylated proline-IFN-alpha-2b approved for treatment of polycythemia vera in adults, regardless of thrombotic risk level or treatment history. Clinical trial data indicate the dose and titration of ropeginterferon alfa-2b is safe and effective. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Albert, Urbanski, Raymond W., Yu, Lennex, Ahmed, Tasfia, Mascarenhas, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913265/
https://www.ncbi.nlm.nih.gov/pubmed/36776307
http://dx.doi.org/10.3389/fonc.2023.1109866

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913265/
https://www.ncbi.nlm.nih.gov/pubmed/36776307
http://dx.doi.org/10.3389/fonc.2023.1109866

Ejemplares similares